Myriad, Biomarin Team Up for BRCA Testing in Phase III
By Catherine Shaffer
Wednesday, October 2, 2013
Myriad Genetics Inc. will return for a repeat engagement of its Phase I collaboration with Biomarin Pharmaceuticals Inc. to deliver BRAC testing for Biomarin’s pivotal Phase III trials of BMN 673. BMN 673 is an oral poly ADP-ribose polymerase (PARP) inhibitor designed to kill BRCA-deficient cancer cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.